FDA and NIH let clinical trial sponsors keep results secret and break the law

Andy · Jan 16, 2020

For 20 years, the U.S. government has urged companies, universities, and other institutions that conduct clinical trials to record their results in a federal database, so doctors and patients can see whether new treatments are safe and effective. Few trial sponsors have consistently done so, even after a 2007 law made posting mandatory for many trials registered in the database. In 2017, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) tried again, enacting a long-awaited “final rule” to clarify the law’s expectations and penalties for failing to disclose trial results. The rule took full effect 2 years ago, on 18 January 2018, giving trial sponsors ample time to comply. But a Science investigation shows that many still ignore the requirement, while federal officials do little or nothing to enforce the law.

Science examined more than 4700 trials whose results should have been posted on the NIH website ClinicalTrials.gov under the 2017 rule. Reporting rates by most large pharmaceutical companies and some universities have improved sharply, but performance by many other trial sponsors—including, ironically, NIH itself—was lackluster. Those sponsors, typically either the institution conducting a trial or its funder, must deposit results and other data within 1 year of completing a trial. But of 184 sponsor organizations with at least five trials due as of 25 September 2019, 30 companies, universities, or medical centers never met a single deadline. As of that date, those habitual violators had failed to report any results for 67% of their trials and averaged 268 days late for those and all trials that missed their deadlines. They included such eminent institutions as the Harvard University–affiliated Boston Children’s Hospital, the University of Minnesota, and Baylor College of Medicine—all among the top 50 recipients of NIH grants in 2019.
Click to expand...

https://www.sciencemag.org/news/202...al-sponsors-keep-results-secret-and-break-law

rvallee · Jan 16, 2020

Refusal to enforce the rule is a choice. Same with optional requirements that BPS research seems to benefit from, that's a choice but unfortunately there is enough support for arbitrary exemptions that this problem persists.

Cui bono? Definitely not the sick.

Log in or Sign up

FDA and NIH let clinical trial sponsors keep results secret and break the law

Andy Committee Member

rvallee Senior Member (Voting Rights)

Share This Page

Log in or Sign up

FDA and NIH let clinical trial sponsors keep results secret and break the law

Andy Committee Member

rvallee Senior Member (Voting Rights)

Share This Page

Useful Searches